Merck & Co. (MRK) 10-Q2023 Q3 Quarterly report

Filed: 3 Nov 23, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ALK, anaplastic, attached, beam, BLA, brachytherapy, checkpoint, chemoradiotherapy, cholesterol, cleavable, community, confirmation, convertase, CORALreef, cytotoxic, Daiichi, deliver, derazantinib, deruxtecan, diagnosed, distant, DXd, EGFR, exatecan, formation, HHS, hypercholesterolemia, ifinatamab, inside, LDL, lipoprotein, Lyfnua, newly, nonrecurrence, notice, oncogene, opt, Orphan, Overnight, patritumab, payload, pemetrexed, permission, proprotein, radiotherapy, raludotatug, ratably, reassessment, refundable, registrational, Sankyo, SCLC, SOFR, subgroup, surface, thirty, topoisomerase, vet

Removed: administered, remitted, shareholder

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MRK transcripts

MRK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Section 1350

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 3, 2023	/s/ Robert M. Davis
	Name: Title:	ROBERT M. DAVIS Chairman and Chief Executive Officer